A retrospective comparison of proton therapy and carbon ion therapy for stage I non-small cell lung cancer

作者：Fujii Osamu^*; Demizu Yusuke; Hashimoto Naoki; Araya Masayuki; Takagi Masaru; Terashima Kazuki; Mima Masayuki; Iwata Hiromitsu; Niwa Yasue; Jin Dongcun; Daimon Takashi; Sasaki Ryohei; Hishikawa Yoshio; Abe Mitsuyuki; Murakami Masao; Fuwa Nobukazu

来源：Radiotherapy and Oncology, 2013, 109(1): 32-37.

DOI：10.1016/j.radonc.2013.08.038

• Particle therapy
• Proton therapy
• Carbon-ion therapy
• Non-small cell lung cancer

Background and purpose: This retrospective study aimed to compare the clinical outcomes and late toxicities of proton therapy (PT) with those of carbon ion therapy (UT) for stage I non-small cell lung cancer (NSCLC). %26lt;br%26gt;Material and methods: A total Of 111 patients who underwent particle therapy for stage I NSCLC between April 2003 and December 2009 were enrolled in this study. PT (n = 70) and CIT (n = 41) were delivered to total doses of 52.8-80 GyE in 4-26 fractions and 52.8-70.2 GyE in 4-26 fractions, respectively. The median follow-up time was 41 months. %26lt;br%26gt;Results: Differences in outcome between the PT and CIT groups regarding 3-year overall survival (72% and 76%, respectively), progression-free survival (44% and 53%, respectively), and local control (81% and 78%, respectively) were not statistically significant. In multivariate analysis, the type of treatment beam did not correlate with overall survival. The severity of late toxicities was comparable between the two groups. %26lt;br%26gt;Conclusions: Clinical results in the PT group were comparable to those in the CIT group. However, this study was a retrospective analysis of a highly heterogeneous population. Consequently, more homogeneous prospective data, large multicentric databases and, ideally, randomized trials are warranted.

• 出版日期2013-10